Racial differences in the diagnosis and treatment of prostate cancer

International Neurourology Journal

Volumn 20, Issue , 2016, Pages 112-119

  Di Pietro, Giuliano ^a   Chornokur, Ganna ^b   Kumar, Nagi B ^b   Davis, Chemar ^b   Park, Jong Y ^b  

^a FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

African Americans; Healthcare disparities; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AGGRESSIVENESS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HEALTH INSURANCE; HUMAN; MALE; MORTALITY RATE; OBESITY; PROSTATE CANCER; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SOCIAL STATUS; WATCHFUL WAITING;

EID: 84999143292     PISSN: 20934777     EISSN: 20936931     Source Type: Journal    
DOI: 10.5213/inj.1632722.361     Document Type: Review

References (39)

1. 2016 Estimates [Internet]. Oklahoma City (OK): American Cancer Society, Cancer Statistics Center; c2016 [Internet]. Available from: https://cancerstatisticscenter.cancer.org/#/.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin 2016;66:290-308.
4. Kelly SP, Rosenberg PS, Anderson WF, Andreotti G, Younes N, Cleary SD, et al. Trends in the incidence of fatal prostate cancer in the United States by race. Eur Urol 2016 Jul 27 [Epub]. https://doi. org/10.1016/j.eururo.2016.05.011.
5. Goins RT, Schure MB, Noonan C, Buchwald D. Prostate cancer screening among American Indians and Alaska natives: the health and retirement survey, 1996-2008. Prev Chronic Dis 2015;12:E123.
6. Kinlock BL, Thorpe RJ Jr, Howard DL, Bowie JV, Ross LE, Fakunle DO, et al. Racial disparity in time between first diagnosis and initial treatment of prostate cancer. Cancer Control 2016;23:47-51.
7. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011;71:985-97.
8. Goovaerts P, Xiao H, Gwede CK, Tan F, Huang Y, Adunlin G, et al. Impact of age, race and socio-economic status on temporal trends in late-stage prostate cancer diagnosis in Florida. Spat Stat 2015; 14(Pt 100):321-37.
9. Kish JK, Yu M, Percy-Laurry A, Altekruse SF. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. J Natl Cancer Inst Monogr 2014;2014:236-43.
10. Trantham LC, Nielsen ME, Mobley LR, Wheeler SB, Carpenter WR, Biddle AK. Use of prostate-specific antigen testing as a disease surveillance tool following radical prostatectomy. Cancer 2013;119: 3523-30.
11. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, et al. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol 2014;5:352-8.
12. Moses KA, Chen LY, Sjoberg DD, Bernstein M, Touijer KA. Black and White men younger than 50 years of age demonstrate similar outcomes after radical prostatectomy. BMC Urol 2014;14:98.
13. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines): Colon/rectal cancer [Internet]. Fort Wathington (PA): National Comprehensive Cancer Network; c2016 [cited 2016 Aug 19]. Available from: http://www.nccn. org/professionals/physician_gls/f_guidelines.asp.
14. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK. Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev 2014;23:1505-11.
15. Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, et al. Getting back to equal: the influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urol Oncol 2014;32:1285-91.
16. Moses KA, Orom H, Brasel A, Gaddy J, Underwood W 3rd. Racial/ethnic differences in the relative risk of receipt of specific treatment among men with prostate cancer. Urol Oncol 2016;34:415.e7-415.e12.
17. Allott EH, Howard LE, Song HJ, Sourbeer KN, Koontz BF, Salama JK, et al. Racial differences in adipose tissue distribution and risk of aggressive prostate cancer among men undergoing radiotherapy. Cancer Epidemiol Biomarkers Prev 2014;23:2404-12.
18. Chornokur G, Amankwah EK, Davis SN, Phelan CM, Park JY, Pow-Sang J, et al. Variation in HNF1B and obesity may influence prostate cancer risk in African American men: a pilot study. Prostate Cancer 2013;2013:384594.
19. Wang EH, Yu JB, Abouassally R, Meropol NJ, Cooper G, Shah ND, et al. Disparities in treatment of patients with high-risk prostate cancer: results from a population-based cohort. Urology 2016;95: 88-94.
20. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. Prostate Cancer 2013;2013:560857.
21. Underwood SM. Reducing the burden of cancer borne by African Americans: if not now, when? Cancer Epidemiol Biomarkers Prev 2003;12:270s-276s.
22. Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY. Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol 2006;175:108-12.
23. Park J, Chen L, Ratnashinge L, Sellers TA, Tanner JP, Lee JH, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006;15:1473-8.
24. Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, et al. Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 2011;20:23-32.
25. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011;43:570-3.
26. Taioli E, Flores-Obando RE, Agalliu I, Blanchet P, Bunker CH, Ferrell RE, et al. Multi-institutional prostate cancer study of genetic susceptibility in populations of African descent. Carcinogenesis 2011;32:1361-5.
27. Han Y, Signorello LB, Strom SS, Kittles RA, Rybicki BA, Stanford JL, et al. Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 2015;136:1210-7.
28. Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, et al. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun 2016;7:10979.
29. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45:385-91, 391e1-2.
30. Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, et al. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet 2015;24:5589-602.
31. Haiman CA, Chen GK, Blot WJ, Strom SS, Berndt SI, Kittles RA, et al. Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. PLoS Genet 2011;7:e1001387.
32. Xu J, Kibel AS, Hu JJ, Turner AR, Pruett K, Zheng SL, et al. Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 2009;18:2145-9.
33. Waters KM, Le Marchand L, Kolonel LN, Monroe KR, Stram DO, Henderson BE, et al. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations. Cancer Epidemiol Biomarkers Prev 2009;18:1285-9.
34. Hooker S, Hernandez W, Chen H, Robbins C, Torres JB, Ahaghotu C, et al. Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans. Prostate 2010;70: 270-5.
35. Cook MB, Wang Z, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA, et al. A genome-wide association study of prostate cancer in West African men. Hum Genet 2014;133:509-21.
36. Powell IJ, Land SJ, Dey J, Heilbrun LK, Hughes MR, Sakr W, et al. The impact of CAG repeats in exon 1 of the androgen receptor on disease progression after prostatectomy. Cancer 2005;103:528-37.
37. Roach M 3rd, De Silvio M, Rebbick T, Grignon D, Rotman M, Wolkov H, et al. Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. Int J Radiat Oncol Biol Phys 2007;69:79-87.
38. Adams SA, Choi SK, Khang L, A Campbell D, Friedman DB, Eberth JM, et al. Decreased cancer mortality-to-incidence ratios with increased accessibility of federally qualified health centers. J Community Health 2015;40:633-41.
39. Prostate Cancer Rates by Race and Ethnicity [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [updated 2016 Jun 16; cited 2016 Aug 30]. Available from: http://www.cdc.gov/cancer/prostate/statistics/race.htm.